- Home
- AOMR vs ZYXI Comparison
AOMR vs ZYXI Comparison
Compare AOMR & ZYXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AOMR
- ZYXI
- Stock Information
- Founded
- AOMR 2018
- ZYXI 1996
- Country
- AOMR United States
- ZYXI United States
- Employees
- AOMR N/A
- ZYXI N/A
- Industry
- AOMR Real Estate Investment Trusts
- ZYXI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- AOMR Real Estate
- ZYXI Health Care
- Exchange
- AOMR Nasdaq
- ZYXI Nasdaq
- Market Cap
- AOMR 238.8M
- ZYXI 44.8M
- IPO Year
- AOMR 2021
- ZYXI N/A
- Fundamental
- Price
- AOMR $9.78
- ZYXI $1.55
- Analyst Decision
- AOMR Strong Buy
- ZYXI Hold
- Analyst Count
- AOMR 6
- ZYXI 3
- Target Price
- AOMR $11.25
- ZYXI $3.00
- AVG Volume (30 Days)
- AOMR 220.4K
- ZYXI 114.2K
- Earning Date
- AOMR 11-05-2025
- ZYXI 10-23-2025
- Dividend Yield
- AOMR 13.04%
- ZYXI N/A
- EPS Growth
- AOMR N/A
- ZYXI N/A
- EPS
- AOMR 1.56
- ZYXI N/A
- Revenue
- AOMR $57,661,000.00
- ZYXI $144,808,000.00
- Revenue This Year
- AOMR N/A
- ZYXI N/A
- Revenue Next Year
- AOMR $13.75
- ZYXI $13.48
- P/E Ratio
- AOMR $6.28
- ZYXI N/A
- Revenue Growth
- AOMR N/A
- ZYXI N/A
- 52 Week Low
- AOMR $7.36
- ZYXI $1.23
- 52 Week High
- AOMR $10.88
- ZYXI $9.42
- Technical
- Relative Strength Index (RSI)
- AOMR 52.04
- ZYXI 44.92
- Support Level
- AOMR $9.71
- ZYXI $1.44
- Resistance Level
- AOMR $9.87
- ZYXI $1.55
- Average True Range (ATR)
- AOMR 0.19
- ZYXI 0.08
- MACD
- AOMR -0.02
- ZYXI 0.02
- Stochastic Oscillator
- AOMR 37.87
- ZYXI 41.00
About AOMR Angel Oak Mortgage REIT Inc.
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in the first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation across interest rates and credit cycles.
About ZYXI Zynex Inc.
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company operates business as one operating segment which includes two revenue types: Devices and Supplies. Its markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.